ImmunityBio | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 32.06 M

Revenue: As of FY2025 Q3, the actual value is USD 32.06 M, beating the estimate of USD 31.88 M.

EPS: As of FY2025 Q3, the actual value is USD -0.07, beating the estimate of USD -0.108.

EBIT: As of FY2025 Q3, the actual value is USD -28.82 M.

Segment Revenue

• Product Revenue, Net: $31.78 million for the three months ended September 30, 2025, compared to $5.95 million for the same period in 2024. For the nine months ended September 30, 2025, product revenue was $74.71 million, compared to $6.94 million in 2024.
• Other Revenues: $0.28 million for the three months ended September 30, 2025, compared to $0.15 million for the same period in 2024. For the nine months ended September 30, 2025, other revenues were $0.29 million, compared to $0.25 million in 2024.

Operational Metrics

• Net Loss: - $67.27 million for the three months ended September 30, 2025, compared to - $85.75 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $289.51 million, compared to - $354.47 million in 2024.
• Gross Profit: $31.88 million for the three months ended September 30, 2025, compared to $6.11 million for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $74.63 million, compared to $7.19 million in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $234.56 million for the nine months ended September 30, 2025, compared to - $306.09 million for the same period in 2024.
• Net Cash Used in Investing Activities: - $193.37 million for the nine months ended September 30, 2025, compared to - $22.08 million for the same period in 2024.
• Net Cash Provided by Financing Activities: $345.35 million for the nine months ended September 30, 2025, compared to $174.70 million for the same period in 2024.

Unique Metrics

• Revenue Interest Liability: $316.15 million as of September 30, 2025, compared to $284.40 million as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the commercialization of its approved product, ANKTIVA, and the development and commercialization of other product candidates. The company anticipates needing additional financing to fund future operations.
• Non-Core Business: The company is exploring potential transitions of clinical trials to new structures and continues discussions with potential partners around alternative structures.